Tyme Technologies (TYME) Granted U.S. Patent Claims Covering Use of TYME-19 to Treat COVID-19 Infections

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that it has received notification that the United States Patent and Trademark Office has granted additional patent claims related to the Company’s metabolomic technology platform. The patent, U.S. Patent No. 10,905,698, is directed to methods for treating COVID-19.

Unlike immune therapies that depend upon the structure of the external virus coat of COVID-19 where the therapy directs its attack, we believe TYME-19 is agnostic to this structure and any mutations to the viral coat. Like other TYME agents, TYME-19 affects cellular metabolism. It constrains viral replication after a virus has inserted its genetic blueprint into an infected cell by inhibiting the ability of the virus to use the cells synthetic apparatus to make viral proteins and lipids. As a result, we believe that TYME-19 diminishes the ability of COVID-19 to hijack an infected cell. TYME intends to initiate the appropriate clinical trials to substantiate the safety and efficacy of TYME-19.

TYME-19 is an investigational compound that is not approved in the U.S. for any disease indication.

You May Also Be Interested In

• Texas AG launches investigation into UnitedHealth Group over coverage denials
• Franco-Nevada acquires 12.42% stake in Kenorland Minerals for $22.2M
• Fortitude Mining signs $100M non-binding deal for Bitmain Zcash miners